Genomma Lab Internacional SAB de CV

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: MX01LA010006
MXN
14.78
-0.32 (-2.12%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

3.71 M

Shareholding (Jun 2018)

FII

0.00%

Held by 1 FIIs

DII

100.00%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

The company is Net-Debt Free

  • Poor long term growth as Operating profit has grown by an annual rate 7.73% of over the last 5 years
  • The company is Net-Debt Free
  • The company has been able to generate a Return on Equity (avg) of 14.48% signifying low profitability per unit of shareholders funds
2

Negative results in Mar 26

3

With ROE of 16.00%, it has a very expensive valuation with a 1.58 Price to Book Value

4

Below par performance in long term as well as near term

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

MXN 15,970 Million (Small Cap)

stock-summary
P/E

10.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.47

stock-summary
Return on Equity

13.69%

stock-summary
Price to Book

1.36

Revenue and Profits:
Net Sales:
4,191 Million
(Quarterly Results - Mar 2026)
Net Profit:
495 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-16.45%
0%
-16.45%
6 Months
-22.33%
0%
-22.33%
1 Year
-32.05%
0%
-32.05%
2 Years
-15.88%
0%
-15.88%
3 Years
0.96%
0%
0.96%
4 Years
-27.3%
0%
-27.3%
5 Years
-26.76%
0%
-26.76%

Genomma Lab Internacional SAB de CV for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
5.89%
EBIT Growth (5y)
7.73%
EBIT to Interest (avg)
3.31
Debt to EBITDA (avg)
1.32
Net Debt to Equity (avg)
0.44
Sales to Capital Employed (avg)
1.00
Tax Ratio
26.38%
Dividend Payout Ratio
48.39%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
22.18%
ROE (avg)
14.48%

Valuation key factors

Factor
Value
P/E Ratio
10
Industry P/E
Price to Book Value
1.58
EV to EBIT
5.83
EV to EBITDA
5.27
EV to Capital Employed
1.40
EV to Sales
1.24
PEG Ratio
0.62
Dividend Yield
NA
ROCE (Latest)
23.98%
ROE (Latest)
16.00%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2018stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 4.32% vs -9.56% in Dec 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 54.76% vs -26.38% in Dec 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4,190.60",
          "val2": "4,017.00",
          "chgp": "4.32%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "963.70",
          "val2": "1,051.20",
          "chgp": "-8.32%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "285.90",
          "val2": "252.90",
          "chgp": "13.05%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "494.60",
          "val2": "319.60",
          "chgp": "54.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "208.30%",
          "val2": "214.40%",
          "chgp": "-0.61%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is -5.73% vs 12.99% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -22.82% vs 92.75% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "17,541.20",
          "val2": "18,606.90",
          "chgp": "-5.73%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "4,135.50",
          "val2": "4,265.00",
          "chgp": "-3.04%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "796.70",
          "val2": "887.80",
          "chgp": "-10.26%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,614.00",
          "val2": "2,091.10",
          "chgp": "-22.82%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "214.10%",
          "val2": "209.90%",
          "chgp": "0.42%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQstock-summary

Mar'26
Dec'25
Change(%)
Net Sales
4,190.60
4,017.00
4.32%
Operating Profit (PBDIT) excl Other Income
963.70
1,051.20
-8.32%
Interest
285.90
252.90
13.05%
Exceptional Items
0.00
0.00
Consolidate Net Profit
494.60
319.60
54.76%
Operating Profit Margin (Excl OI)
208.30%
214.40%
-0.61%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Mar 2026 is 4.32% vs -9.56% in Dec 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Mar 2026 is 54.76% vs -26.38% in Dec 2025

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
17,541.20
18,606.90
-5.73%
Operating Profit (PBDIT) excl Other Income
4,135.50
4,265.00
-3.04%
Interest
796.70
887.80
-10.26%
Exceptional Items
0.00
0.00
Consolidate Net Profit
1,614.00
2,091.10
-22.82%
Operating Profit Margin (Excl OI)
214.10%
209.90%
0.42%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is -5.73% vs 12.99% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -22.82% vs 92.75% in Dec 2024

stock-summaryCompany CV
About Genomma Lab Internacional SAB de CV stock-summary
stock-summary
Genomma Lab Internacional SAB de CV
Pharmaceuticals & Biotechnology
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company’s product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
Company Coordinates stock-summary
Company Details
Edificio Samara, Antonio Dovali Jaime no. 70 Piso 2, Colonia Santa Fe, MEXICO, D.F. None : 01210
Registrar Details